CD151 and breast cancer: The breast cancer patients with CD151 overexpression demonstrated substantially poorer OS (CD151-high vs CD151-low; 109.8 months (95% confidence interval (CI), 100.9–118.7 months) vs 134.1 months (95% CI, 131.3–137.0 months), P<0.001) and DFS (CD151-high vs CD151-low; 104.2 months (95% CI, 94.6–113.7 months) vs 120.0 months (95% CI, 116.2–123.7 months), P=0.020) (Figure 2A).